Cargando…

Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?

Detalles Bibliográficos
Autores principales: Wang, Jun, Hui, Zhouguang, Pang, Qingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626336/
https://www.ncbi.nlm.nih.gov/pubmed/36214057
http://dx.doi.org/10.1111/1759-7714.14641
_version_ 1784822708227276800
author Wang, Jun
Hui, Zhouguang
Pang, Qingsong
author_facet Wang, Jun
Hui, Zhouguang
Pang, Qingsong
author_sort Wang, Jun
collection PubMed
description
format Online
Article
Text
id pubmed-9626336
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-96263362022-11-03 Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma? Wang, Jun Hui, Zhouguang Pang, Qingsong Thorac Cancer Letters to the Editor John Wiley & Sons Australia, Ltd 2022-10-10 2022-11 /pmc/articles/PMC9626336/ /pubmed/36214057 http://dx.doi.org/10.1111/1759-7714.14641 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letters to the Editor
Wang, Jun
Hui, Zhouguang
Pang, Qingsong
Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
title Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
title_full Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
title_fullStr Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
title_full_unstemmed Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
title_short Is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
title_sort is adjuvant immunotherapy a new standard for non‐pathological complete response patients with resectable esophageal squamous cell carcinoma?
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626336/
https://www.ncbi.nlm.nih.gov/pubmed/36214057
http://dx.doi.org/10.1111/1759-7714.14641
work_keys_str_mv AT wangjun isadjuvantimmunotherapyanewstandardfornonpathologicalcompleteresponsepatientswithresectableesophagealsquamouscellcarcinoma
AT huizhouguang isadjuvantimmunotherapyanewstandardfornonpathologicalcompleteresponsepatientswithresectableesophagealsquamouscellcarcinoma
AT pangqingsong isadjuvantimmunotherapyanewstandardfornonpathologicalcompleteresponsepatientswithresectableesophagealsquamouscellcarcinoma